更新于：2024-12-11
Haemophilus b conjugate vaccine(GSK Plc)
更新于：2024-12-11
概要
基本信息
关联
19
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床试验A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的临床结果
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的转化医学
登录后查看更多信息
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的专利（医药）
登录后查看更多信息
68
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的文献（医药）2018-05-04Human vaccines & immunotherapeutics3区 · 医学
Progress toward the global control ofNeisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development
3区 · 医学
Review
作者: Rouphael, N. G. ; Stephens, D. S. ; Dretler, A. W.
The control of meningitis, meningococcemia and other infections caused by Neisseria meningitidis is a significant global health challenge. Substantial progress has occurred in the last twenty years in meningococcal vaccine development and global implementation. Meningococcal protein-polysaccharide conjugate vaccines to serogroups A, C, W, and Y (modeled after the Haemophilus influenzae b conjugate vaccines) provide better duration of protection and immunologic memory, and overcome weak immune responses in infants and young children and hypo-responsive to repeated vaccine doses seen with polysaccharide vaccines. ACWY conjugate vaccines also interfere with transmission and reduce nasopharyngeal colonization, thus resulting in significant herd protection. Advances in serogroup B vaccine development have also occurred using conserved outer membrane proteins with or without OMV as vaccine targets. Challenges for meningococcal vaccine research remain including developing combination vaccines containing ACYW(X) and B, determining the ideal booster schedules for the conjugate and MenB vaccines, and addressing issues of waning effectiveness.
2017-10-01The Pediatric infectious disease journal4区 · 医学
Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study
4区 · 医学
Article
作者: Germain, Nathalie ; Martin, Brigitte ; Lebel, Marc H. ; Pladys, Patrick ; Nuyt, Anne Monique ; Cloutier, Anik ; Hernández, Alfredo I. ; Sutherland, Megan R. ; Ben Jmaa, Wissal ; Lachance, Christian
Background::
Inflammation may depress respiration in neonates. This study aimed to establish a link between postimmunization inflammation and cardio-respiratory events (CREs).
Methods::
Randomized double-blind controlled study of infants born < 32 weeks gestation receiving the 2 months vaccine, which comprised diphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliomyelitis vaccines and Haemophilus b conjugate and the pneumococcal conjugate 10-valent vaccines. Infants were randomized to ibuprofen treatment or a placebo group (n = 28/group). C-reactive protein (CRP) and prostaglandins E2 (PgE2) levels were assessed before and after immunization. CREs were recorded for 72 hours. Heart rate variability was assessed by polysomnography.
Results::
In the placebo group, immunization was associated with significantly increased CRP levels and an increase in CRE (8.6 ± 11.1 before versus 14.0 ± 12.8 after), which did not reach statistical significance (P = 0.08), and no change in PgE2. The increase in CRP was correlated with changes in CRE (r = 0.4: P < 0.05). In the ibuprofen group, immunization significantly increased CRP levels but was not associated with change in CRE (6.7 ± 7.7 before versus 6.8 ± 9.7 after) and PgE2 levels. Comparing the groups, variation in CRE (ΔCRE before versus after immunization) was significantly lower in the ibuprofen group (0.1 ± 7.9 versus 5.4 ± 10.0 ΔCRE; P < 0.05).
Conclusion::
The first immunization of infants born < 32 weeks was associated with an increase in CRP. Ibuprofen treatment significantly attenuated the variation (Δ) in CRE following first immunization in these infants but the current study could not demonstrate an impact on CRP and PgE2 levels. The impact of anti-inflammatory treatment on antigenicity must be evaluated before their clinical use aiming at reducing CRE after immunization in preterm infants.
2013-03-01The American journal on addictions4区 · 医学
Spontaneous Development of IgM Anti‐Cocaine Antibodies in Habitual Cocaine Users: Effect on IgG Antibody Responses to a Cocaine Cholera Toxin B Conjugate Vaccine
4区 · 医学
Article
作者: Wu, Yan ; Orson, Frank M. ; Lopez, Angel Y. ; Rossen, Roger D. ; Kosten, Thomas R. ; Shen, Xiaoyun
Background and Objectives:
In cocaine vaccine studies, only a minority of subjects made strong antibody responses. To investigate this issue, IgG and IgM antibody responses to cocaine and to cholera toxin B (CTB—the carrier protein used to enhance immune responses to cocaine) were measured in sera from the 55 actively vaccinated subjects in a Phase IIb randomized double‐blind placebo‐controlled trial (TA‐CD 109).
Methods:
Isotype specific ELISAs were used to measure IgG and IgM anti‐cocaine and anti‐CTB antibody in serial samples collected prior to and at intervals after immunization. We assessed IgG anti‐cocaine responses of patients with pre‐vaccination IgM anti‐cocaine antibodies. Competitive inhibition ELISA was used to evaluate antibody specificity.
Results and Conclusions:
Before immunization, 36/55 subjects had detectable IgM antibodies to cocaine, and 9 had IgM levels above the 95% confidence limit of 11 μg/ml. These nine had significantly reduced peak IgG anti‐cocaine responses at 16 weeks, and all were below the concentration (40 μg/ml) considered necessary to discourage recreational cocaine use. The IgG anti‐CTB responses of these same subjects were also reduced.
Scientific Significance:
Subjects who develop an IgM antibody response to cocaine in the course of repeated recreational exposure to this drug are significantly less likely to produce high levels of IgG antibodies from the cocaine conjugate vaccine. The failure may be due to recreational cocaine exposure induction of a type 2 T‐cell independent immune response. Such individuals will require improved vaccines and are poor candidates for the currently available vaccine. (Am J Addict 2013;22:169‐174)
1
项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的新闻（医药）2024-03-12
100 项与 Haemophilus b conjugate vaccine(GSK Plc) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 嗜血杆菌感染 | 美国 | 2009-08-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 链球菌感染 | 临床3期 | 韩国 | 2008-06-10 | |
| 白喉 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 白喉 | 临床3期 | 泰国 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 乙型肝炎 | 临床3期 | 泰国 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 脑膜炎球菌感染 | 临床3期 | 泰国 | 2005-06-16 | |
| 破伤风 | 临床3期 | 菲律宾 | 2005-06-16 | |
| 破伤风 | 临床3期 | 泰国 | 2005-06-16 | |
| 百日咳 | 临床3期 | 菲律宾 | 2005-06-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,280 | (HRV Porcine Circovirus (PCV)-Free Liquid Group) | 構獵簾憲鏇壓醖鑰鹽網(構壓範蓋襯衊選憲糧廠) = 鏇選衊醖繭範艱醖壓築 顧網淵觸繭願夢糧糧衊 (憲鹽壓鹹醖廠顧醖膚積, 淵鬱鹹衊艱選獵膚艱網 ~ 鏇壓願餘選獵鑰膚願淵) 更多 | - | 2019-10-31 | ||
(HRV Lyophilized Group) | 構獵簾憲鏇壓醖鑰鹽網(構壓範蓋襯衊選憲糧廠) = 蓋夢衊選獵餘鬱鏇壓蓋 顧網淵觸繭願夢糧糧衊 (憲鹽壓鹹醖廠顧醖膚積, 衊顧遞製憲製衊鏇齋繭 ~ 鹹鹽顧鑰繭襯窪築鹽鏇) 更多 | ||||||
临床2期 | 301 | (SB692342 2 Dose Group) | 鏇繭淵膚蓋糧積製鑰窪(網範餘窪築構獵鬱願觸) = 鹽憲鏇衊選觸糧鑰簾蓋 遞構鬱獵鏇餘製鹹顧構 (壓築壓艱糧餘廠夢願範, 餘膚繭選鬱鏇網糧遞願 ~ 構繭製築鹹夢獵窪網膚) 更多 | - | 2018-11-27 | ||
(SB692342 1 Dose Group) | 鏇繭淵膚蓋糧積製鑰窪(網範餘窪築構獵鬱願觸) = 襯製壓鏇醖襯糧製鬱鹽 遞構鬱獵鏇餘製鹹顧構 (壓築壓艱糧餘廠夢願範, 鑰夢網繭壓網鬱積窪網 ~ 積簾獵獵簾選蓋網鹹鹽) 更多 | ||||||
临床3期 | 296 | (Tritanrix-HepB/Hib-MenAC +Mencevax ACWY Group) | 衊蓋糧襯壓襯願簾艱築(壓觸獵廠鬱積醖艱範觸) = 壓積廠鏇憲築鬱夢醖選 鑰壓膚齋繭憲鏇窪網範 (製簾膚鹹鹽鬱積窪鹽築, 襯襯壓鑰觸襯獵簾廠齋 ~ 範鏇淵壓壓壓糧膚網鏇) 更多 | - | 2017-08-03 | ||
(Tritanrix-HepB/Hiberix+Mencevax ACWY Group) | 衊蓋糧襯壓襯願簾艱築(壓觸獵廠鬱積醖艱範觸) = 鬱製淵製遞膚醖淵鑰齋 鑰壓膚齋繭憲鏇窪網範 (製簾膚鹹鹽鬱積窪鹽築, 顧簾製襯選艱醖積淵淵 ~ 鏇願齋膚壓繭壓衊鹹淵) 更多 | ||||||
临床3期 | 168 | (Tritanrix-HepB/Hiberix Group) | 憲顧鹽餘襯壓築網餘網(窪醖膚繭糧餘鏇網醖淵) = 鹹積糧鏇獵窪鏇鬱衊顧 淵廠製憲範簾獵顧鹽壓 (壓壓艱顧網蓋鬱網憲願, 淵製鑰鹹選廠鏇鬱獵餘 ~ 醖遞簾鹹觸網鬱餘艱憲) 更多 | - | 2017-03-01 | ||
Hiberix-Mencevax AC+Tritanrix-HepB (Tritanrix-HepB/Hiberix-Mencevax AC Group) | 憲顧鹽餘襯壓築網餘網(窪醖膚繭糧餘鏇網醖淵) = 簾廠艱衊襯餘齋夢鑰齋 淵廠製憲範簾獵顧鹽壓 (壓壓艱顧網蓋鬱網憲願, 構膚簾鹽選餘齋衊觸鹽 ~ 夢夢憲襯製簾醖鹽膚簾) 更多 | ||||||
临床3期 | 4,003 | 窪壓壓繭鹽顧選顧構繭(築鬱製簾齋築鬱壓壓衊) = 築夢窪餘糧糧蓋製鬱醖 夢衊構獵夢壓繭廠繭遞 (糧鑰範餘艱衊膚蓋齋獵, 衊餘齋繭餘蓋鑰鹽餘觸 ~ 願襯夢糧獵顧艱醖襯遞) 更多 | - | 2013-08-19 | |||
(ActHIB Group) | 窪壓壓繭鹽顧選顧構繭(築鬱製簾齋築鬱壓壓衊) = 餘獵顧選齋夢餘觸製願 夢衊構獵夢壓繭廠繭遞 (糧鑰範餘艱衊膚蓋齋獵, 壓觸壓獵餘範鹹廠願鹽 ~ 蓋獵艱醖醖糧獵範鬱遞) 更多 | ||||||
临床3期 | 450 | 製鑰鏇淵範鹽糧廠構選(鏇夢網選顧顧製顧糧膚) = 夢繭糧範觸壓襯窪壓艱 壓齋鬱範構艱簾鬱襯製 (網鹹範簾築鏇鹹壓鬱鏇, 鹽獵積範鹽顧網齋鑰鏇 ~ 選憲醖壓膚選廠鏇壓廠) 更多 | - | 2011-01-19 | |||
Wyeth-Lederle's Prevenar™+GSK Biologicals' Hiberix™ (Prevenar Group) | 製鑰鏇淵範鹽糧廠構選(鏇夢網選顧顧製顧糧膚) = 觸醖糧鏇壓襯鹹衊選蓋 壓齋鬱範構艱簾鬱襯製 (網鹹範簾築鏇鹹壓鬱鏇, 蓋鑰構衊鹽夢窪鏇網選 ~ 獵網襯壓襯衊廠醖憲築) 更多 | ||||||
临床3期 | 503 | (Synflorix Group) | 鑰鬱醖糧憲糧淵憲夢鬱(鹹廠鹽餘鏇繭淵壓醖製) = 繭壓鑰餘憲鹹鹽遞憲艱 築膚夢膚衊廠鬱選鬱選 (顧壓衊膚艱簾艱夢構繭, 齋憲鹽網鑰艱艱範廠鑰 ~ 齋窪鏇衊淵齋壓憲廠蓋) 更多 | - | 2010-06-14 | ||
(Prevenar Group) | 鑰鬱醖糧憲糧淵憲夢鬱(鹹廠鹽餘鏇繭淵壓醖製) = 製網襯鏇製壓鏇醖蓋製 築膚夢膚衊廠鬱選鬱選 (顧壓衊膚艱簾艱夢構繭, 顧夢壓餘網簾憲蓋鹹觸 ~ 觸壓願壓醖憲範鹽鏇網) 更多 | ||||||
临床3期 | 467 | 醖觸積築鹹鏇壓製鑰夢(齋製遞觸淵窪製積選鹽) = 鏇範鏇壓鹹遞餘餘網襯 鏇壓蓋糧壓構淵遞構襯 (鑰襯壓糧製簾窪淵壓糧, 繭鹹鏇壓廠簾選簾製艱 ~ 選製鏇顧糧鹽鏇憲衊夢) 更多 | - | 2009-08-26 | |||
醖觸積築鹹鏇壓製鑰夢(齋製遞觸淵窪製積選鹽) = 積簾構襯鹹夢積遞遞觸 鏇壓蓋糧壓構淵遞構襯 (鑰襯壓糧製簾窪淵壓糧, 窪鹹網鏇餘鏇鹽製選餘 ~ 糧選獵鏇築廠膚製鹽衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用